Clinical Trials Logo

Clinical Trial Summary

The investigators will conduct a n=5,400 Phase 3, double-blind, individually randomised placebo-controlled clinical trial of 5 years' duration in primary schools in City of Cape Town Metropolitan Municipality, Western Cape Province, Republic of South Africa. The primary objective of the trial is to determine whether a weekly oral dose of 0.25 mg (10,000 IU) vitamin D3, administered for three years, reduces risk of acquisition of latent tuberculosis infection (LTBI) in Cape Town primary schoolchildren. Statistical analysis will be performed on an intention-to-treat basis to compare acquisition of LTBI in intervention vs. control arms during three-year follow-up. The primary analysis will be logistic regression with presence/absence of LTBI at follow-up as the outcome, adjusted for a random effect of school of attendance.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02880982
Study type Interventional
Source Queen Mary University of London
Contact
Status Completed
Phase Phase 3
Start date March 14, 2017
Completion date June 30, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05073926 - Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
Not yet recruiting NCT04428294 - Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation Phase 4
Completed NCT02276755 - Vitamin D Supplementation in TB Prevention Phase 3
Withdrawn NCT03498534 - Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis Phase 4
Active, not recruiting NCT03988933 - 2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB. Phase 2
Recruiting NCT06022146 - TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts Phase 3
Active, not recruiting NCT04188041 - Improving Rhode Island's Tuberculosis Preventive Services in Primary Care N/A
Recruiting NCT03730181 - Tuberculosis Clinical Trials Consortium Study 35 Phase 1/Phase 2
Completed NCT01967134 - Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis Phase 1
Completed NCT00257907 - Immune Response to Mycobacterium Tuberculosis Infection
Recruiting NCT05756582 - Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students
Active, not recruiting NCT04557176 - TB Screening Improves Preventive Therapy Uptake N/A
Completed NCT02119130 - Quantiferon Gold Test for Detecting Tuberculosis (TB) Infection in HIV/AIDS Patients in South Africa N/A
Not yet recruiting NCT06281834 - Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention Phase 1
Not yet recruiting NCT02512484 - Improving the Detection of Active Tuberculosis in Accident and Emergency Departments N/A
Completed NCT00763295 - Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV? N/A
Completed NCT01850043 - The Epidemiology of TST Change in Korea N/A
Completed NCT02073669 - Latent Tuberculosis in Second Generation Immigrants From High Risk Countries Compare to Low-risk Young Israeli Adults N/A
Completed NCT02090374 - Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen N/A
Withdrawn NCT03783728 - Video Based Directly Observed Therapy for Latent TB